Marinus Pharmaceuticals has been granted a patent for a method to treat tuberous sclerosis complex-related epilepsy by administering ganaxolone. The method involves using a pharmaceutically acceptable pregnenolone neurosteroid to reduce symptoms. GlobalData’s report on Marinus Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Marinus Pharmaceuticals, Nanoparticle drug conjugates was a key innovation area identified from patents. Marinus Pharmaceuticals's grant share as of May 2024 was 17%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of tuberous sclerosis-related epilepsy using ganaxolone
A recently granted patent (Publication Number: US11980625B2) discloses a method for treating tuberous sclerosis-related epilepsy by administering ganaxolone to a subject in need. The method involves administering a therapeutically effective amount of ganaxolone, with options for oral administration as an oral suspension, capsule, or tablet. The dosage is specified to achieve a ganaxolone plasma concentration of at least 100 ng/ml for at least 70% of the day, with daily limits ranging from 1500 mg to 1800 mg, depending on the specific dosage regimen.
Furthermore, the patent outlines variations in dosage based on body weight, with a maximum of 63 mg/kg per day recommended. The method allows for flexibility in dosing frequency, with options for administration three times per day to maintain the required plasma concentration levels. Additionally, intravenous infusion is also mentioned as a potential method of administration for ganaxolone. Overall, the patent provides detailed guidance on the use of ganaxolone in treating tuberous sclerosis-related epilepsy, emphasizing the importance of achieving and maintaining specific plasma concentration levels for optimal therapeutic effect.
To know more about GlobalData’s detailed insights on Marinus Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
